Trinity Biotech Past Earnings Performance
Past criteria checks 0/6
Trinity BiotechDie Erträge des Sektors -3.2% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Medical Equipment growing auf 9.1% pro Jahr stiegen. Die Einnahmen sind declining mit einer durchschnittlichen Rate von 5.1% pro Jahr gesunken.
Key information
-3.2%
Earnings growth rate
13.6%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | -5.1% |
| Return on equity | n/a |
| Net Margin | -54.9% |
| Next Earnings Update | 04 Apr 2024 |
Recent past performance updates
Recent updates
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%
Mar 02
Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry
Dec 18A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)
Sep 12Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?
Aug 08Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price
Jun 09Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)
Apr 23This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts
Apr 23Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 01Trinity Biotech appoints former GE executive Aris Kekedjian as CEO
Oct 03At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?
Sep 01Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M
Jun 30Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)
Jun 14Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 23Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?
Feb 25Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability
Feb 02
A Treatise On Trinity Biotech
Jan 13Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?
Jan 05What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?
Dec 10Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt
Nov 19Trinity Biotech EPS beats by $0.22, beats on revenue
Nov 17Revenue & Expenses BreakdownBeta
How Trinity Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 71 | -39 | 36 | 4 |
| 30 Jun 23 | 72 | -42 | 34 | 4 |
| 31 Mar 23 | 74 | -34 | 32 | 4 |
| 31 Dec 22 | 75 | -41 | 29 | 4 |
| 30 Sep 22 | 76 | -32 | 25 | 4 |
| 30 Jun 22 | 79 | -22 | 25 | 4 |
| 31 Mar 22 | 86 | -13 | 24 | 4 |
| 31 Dec 21 | 93 | 1 | 25 | 4 |
| 30 Sep 21 | 106 | -8 | 26 | 5 |
| 30 Jun 21 | 116 | -2 | 27 | 5 |
| 31 Mar 21 | 106 | -2 | 25 | 5 |
| 31 Dec 20 | 102 | -6 | 25 | 5 |
| 30 Sep 20 | 91 | -20 | 30 | 5 |
| 30 Jun 20 | 83 | -27 | 31 | 5 |
| 31 Mar 20 | 90 | -31 | 27 | 5 |
| 31 Dec 19 | 90 | -29 | 33 | 5 |
| 30 Sep 19 | 94 | -30 | 28 | 5 |
| 30 Jun 19 | 93 | -29 | 28 | 5 |
| 31 Mar 19 | 95 | -23 | 29 | 5 |
| 31 Dec 18 | 97 | -23 | 29 | 5 |
| 30 Sep 18 | 97 | -39 | 30 | 6 |
| 30 Jun 18 | 99 | -40 | 31 | 6 |
| 31 Mar 18 | 99 | -40 | 31 | 6 |
| 31 Dec 17 | 99 | -39 | 31 | 6 |
| 30 Sep 17 | 98 | -36 | 30 | 5 |
| 30 Jun 17 | 99 | -37 | 30 | 5 |
| 31 Mar 17 | 100 | -36 | 30 | 5 |
| 31 Dec 16 | 100 | -39 | 30 | 5 |
| 30 Sep 16 | 101 | 3 | 29 | 5 |
| 30 Jun 16 | 101 | 16 | 30 | 5 |
| 31 Mar 16 | 98 | 16 | 28 | 5 |
| 31 Dec 15 | 100 | 22 | 28 | 5 |
| 30 Sep 15 | 101 | 23 | 31 | 5 |
| 30 Jun 15 | 103 | 15 | 31 | 4 |
| 31 Mar 15 | 105 | 17 | 30 | 4 |
| 31 Dec 14 | 105 | 15 | 30 | 4 |
| 30 Sep 14 | 103 | 18 | 30 | 4 |
| 30 Jun 14 | 100 | 10 | 29 | 4 |
| 31 Mar 14 | 95 | 10 | 28 | 4 |
| 31 Dec 13 | 91 | 10 | 27 | 4 |
| 30 Sep 13 | 86 | 9 | 23 | 3 |
| 30 Jun 13 | 83 | 17 | 22 | 3 |
Qualität der Erträge: TRIB ist derzeit unrentabel.
Wachsende Gewinnspanne: TRIB ist derzeit unrentabel.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Ergebnisentwicklung: TRIB ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 3.2% pro Jahr zugenommen.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von TRIB verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: TRIB ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Medical Equipment (3.7%) erschwert.
Return on Equity
Hohe Eigenkapitalrendite: TRIBDie Verbindlichkeiten des Unternehmens übersteigen seine Vermögenswerte, so dass es schwierig ist, seine Eigenkapitalrendite zu berechnen.